These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30607817)

  • 41. Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study.
    Jankowitz RC; Abraham J; Tan AR; Limentani SA; Tierno MB; Adamson LM; Buyse M; Wolmark N; Jacobs SA
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1205-12. PubMed ID: 24077916
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.
    Oaknin A; Friedman CF; Roman LD; D'Souza A; Brana I; Bidard FC; Goldman J; Alvarez EA; Boni V; ElNaggar AC; Passalacqua R; Do KTM; Santin AD; Keyvanjah K; Xu F; Eli LD; Lalani AS; Bryce RP; Hyman DM; Meric-Bernstam F; Solit DB; Monk BJ
    Gynecol Oncol; 2020 Oct; 159(1):150-156. PubMed ID: 32723675
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
    Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A
    Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adaptive Randomization of Neratinib in Early Breast Cancer.
    Park JW; Liu MC; Yee D; Yau C; van 't Veer LJ; Symmans WF; Paoloni M; Perlmutter J; Hylton NM; Hogarth M; DeMichele A; Buxton MB; Chien AJ; Wallace AM; Boughey JC; Haddad TC; Chui SY; Kemmer KA; Kaplan HG; Isaacs C; Nanda R; Tripathy D; Albain KS; Edmiston KK; Elias AD; Northfelt DW; Pusztai L; Moulder SL; Lang JE; Viscusi RK; Euhus DM; Haley BB; Khan QJ; Wood WC; Melisko M; Schwab R; Helsten T; Lyandres J; Davis SE; Hirst GL; Sanil A; Esserman LJ; Berry DA;
    N Engl J Med; 2016 Jul; 375(1):11-22. PubMed ID: 27406346
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Trastuzumab Targeted Neratinib Loaded Poly-Amidoamine Dendrimer Nanocapsules for Breast Cancer Therapy.
    Aleanizy FS; Alqahtani FY; Seto S; Al Khalil N; Aleshaiwi L; Alghamdi M; Alquadeib B; Alkahtani H; Aldarwesh A; Alqahtani QH; Abdelhady HG; Alsarra I
    Int J Nanomedicine; 2020; 15():5433-5443. PubMed ID: 32801698
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neratinib for HER2-positive breast cancer with an overlooked option.
    Guo L; Shao W; Zhou C; Yang H; Yang L; Cai Q; Wang J; Shi Y; Huang L; Zhang J
    Mol Med; 2023 Oct; 29(1):134. PubMed ID: 37803271
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer.
    Jackisch C; Barcenas CH; Bartsch R; Palma JD; Glück S; Harbeck N; Macedo G; O'Shaughnessy J; Pistilli B; Ruiz-Borrego M; Rugo HS
    Clin Breast Cancer; 2021 Oct; 21(5):e575-e583. PubMed ID: 33678567
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis.
    Nasrazadani A; Brufsky A
    Future Oncol; 2020 Mar; 16(7):247-254. PubMed ID: 32057254
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer.
    Chan A; Ruiz-Borrego M; Marx G; Chien AJ; Rugo HS; Brufsky A; Thirlwell M; Trudeau M; Bose R; García-Sáenz JA; Egle D; Pistilli B; Wassermann J; Cheong KA; Schnappauf B; Semsek D; Singer CF; Foruzan N; DiPrimeo D; McCulloch L; Hurvitz SA; Barcenas CH
    Breast; 2023 Feb; 67():94-101. PubMed ID: 36702070
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An Acquired
    Hanker AB; Brewer MR; Sheehan JH; Koch JP; Sliwoski GR; Nagy R; Lanman R; Berger MF; Hyman DM; Solit DB; He J; Miller V; Cutler RE; Lalani AS; Cross D; Lovly CM; Meiler J; Arteaga CL
    Cancer Discov; 2017 Jun; 7(6):575-585. PubMed ID: 28274957
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials.
    Tao Z; Li SX; Shen K; Zhao Y; Zeng H; Ma X
    Clin Drug Investig; 2019 Jan; 39(1):27-43. PubMed ID: 30370488
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer.
    Duchnowska R; Loibl S; Jassem J
    Cancer Treat Rev; 2018 Jun; 67():71-77. PubMed ID: 29772459
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neratinib (Nerlynx) for HER2-positive breast cancer.
    Med Lett Drugs Ther; 2018 Jan; 60(1539):23. PubMed ID: 29364199
    [No Abstract]   [Full Text] [Related]  

  • 54. How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer.
    Untch M; Martin M; De Laurentiis M; Gligorov J
    Oncol Ther; 2021 Dec; 9(2):297-309. PubMed ID: 34057699
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer.
    Oliveira M; Garrigós L; Assaf JD; Escrivá-de-Romaní S; Saura C
    Expert Rev Anticancer Ther; 2020 Sep; 20(9):731-741. PubMed ID: 32862744
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adverse cutaneous effects of neratinib.
    Hamid RN; Ahn CS; Huang WW
    J Dermatolog Treat; 2019 Aug; 30(5):487-488. PubMed ID: 30321080
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Position Paper on the Value of Extended Adjuvant Therapy with Neratinib for Early HER2+/HR+ Breast Cancer.
    Balic M; Rinnerthaler G; Bartsch R
    Breast Care (Basel); 2021 Dec; 16(6):664-676. PubMed ID: 35082573
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.
    Abraham J; Montero AJ; Jankowitz RC; Salkeni MA; Beumer JH; Kiesel BF; Piette F; Adamson LM; Nagy RJ; Lanman RB; Sperinde J; Huang W; Allegra CJ; Srinivasan A; Wang Y; Pogue-Geile KL; Lucas PC; Jacobs SA
    J Clin Oncol; 2019 Oct; 37(29):2601-2609. PubMed ID: 31442103
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Beyond trastuzumab: new treatment options for HER2-positive breast cancer.
    Saini KS; Azim HA; Metzger-Filho O; Loi S; Sotiriou C; de Azambuja E; Piccart M
    Breast; 2011 Oct; 20 Suppl 3():S20-7. PubMed ID: 22015288
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer.
    Bose P; Ozer H
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1735-51. PubMed ID: 19780706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.